<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797831</url>
  </required_header>
  <id_info>
    <org_study_id>KRT-232-118</org_study_id>
    <nct_id>NCT05797831</nct_id>
  </id_info>
  <brief_title>Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer</brief_title>
  <official_title>A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kartos Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates navtemadlin as maintenance treatment for patients with advanced or&#xD;
      recurrent endometrial cancer (EC) who have achieved complete response or partial response on&#xD;
      chemotherapy.&#xD;
&#xD;
      The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two&#xD;
      different doses of navtemadlin alongside an observational control arm to determine the Phase&#xD;
      3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose&#xD;
      compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2023</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: To determine the navtemadlin Phase 3 dose</measure>
    <time_frame>12 months</time_frame>
    <description>Safety review committee (SRC) will determine the navtemadlin Phase 3 dose for Part 2 based on safety data from Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: To compare progression-free (PFS) survival by independent review committee (IRC) between navtemadlin and placebo</measure>
    <time_frame>50 months</time_frame>
    <description>PFS defined as the time from randomization to disease progression by IRC or death, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: To evaluate the treatment effect of navtemadlin on PFS by IRC and investigator assessment</measure>
    <time_frame>50 months</time_frame>
    <description>PFS defined as the time from randomization to disease progression by IRC/investigator assessment or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: To evaluate the treatment effect of navtemadlin on the time to first subsequent treatment (TFST)</measure>
    <time_frame>50 months</time_frame>
    <description>TFST defined as the time from randomization to initiation of first subsequent anticancer therapy or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: To determine the pharmacokinetic (PK) profile of navtemadlin</measure>
    <time_frame>1 day</time_frame>
    <description>Will determine the Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: To determine the pharmacokinetic (PK) profile of navtemadlin</measure>
    <time_frame>1 day</time_frame>
    <description>Will determine the area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: To determine the pharmacokinetic (PK) profile of navtemadlin</measure>
    <time_frame>1 day</time_frame>
    <description>Will determine the time of maximum plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: To evaluate the treatment effect of navtemadlin on the disease control rate (DCR)</measure>
    <time_frame>50 months</time_frame>
    <description>Best response of complete response (CR), partial response (PR) or stable disease (SD) by IRC/investigator assessment among subjects with PR as best response from prior chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Navtemadlin administered orally at 180 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Navtemadlin administered orally at 240 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Arm 3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observational control (&quot;watch and wait&quot;) on a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Navtemadlin administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Navtemadlin administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navtemadlin</intervention_name>
    <description>Navtemadlin is an experimental MDM2 anticancer drug taken by mouth</description>
    <arm_group_label>Part 1 Arm 1</arm_group_label>
    <arm_group_label>Part 1 Arm 2</arm_group_label>
    <arm_group_label>Part 2 Arm A</arm_group_label>
    <arm_group_label>Part 2 Arm B</arm_group_label>
    <other_name>KRT-232</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navtemadlin Placebo</intervention_name>
    <description>Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth</description>
    <arm_group_label>Part 2 Arm C</arm_group_label>
    <arm_group_label>Part 2 Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of endometrial cancer documented&#xD;
             as TP53WT&#xD;
&#xD;
          -  Subjects with advanced or recurrent disease must have completed a single line of up to&#xD;
             6 cycles of taxane-platinum based chemo and achieved a CR or PR per RECIST V1.1&#xD;
&#xD;
          -  Adequate hematologic, hepatic and renal function (within 14 days)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has any sarcomas or small-cell carcinomas with neuroendocrine differentiation&#xD;
&#xD;
          -  Prior immune therapy, cytokine therapy, or any investigational therapy (within 28&#xD;
             days)&#xD;
&#xD;
          -  Indwelling surgical drains&#xD;
&#xD;
          -  Grade 2 or higher QTc prolongation&#xD;
&#xD;
          -  History of major organ transplant&#xD;
&#xD;
          -  History of bleeding diathesis; major hemorrhage or intracranial hemorrhage (within 24&#xD;
             weeks)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Mei</last_name>
    <phone>650-542-0136</phone>
    <email>jmei@kartosthera.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 7, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>navtemadlin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

